Tumorigenicity of mouse BALB/c 3T3 fibroblast cells which express Epstein-Barr virus-encoded LMP1 and show normal growth phenotypes in vitro is correlated with loss of transforming growth factor-β1-mediated growth inhibition

Archives of Virology

Volumn 144, Issue 2, 1999, Pages 241-257

  Takanashi, M ^a   Li, J ^a   Shirakata, M ^a   Mori, S ^b   Hirai, K ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CARCINOGENICITY; CELL ADHESION MOLECULE; CLONE; COMBINED IMMUNODEFICIENCY; EPSTEIN BARR VIRUS; FIBROBLAST; GROWTH INHIBITION; LATENT MEMBRANE PROTEIN 1; MOUSE; PHENOTYPE; PROTEIN EXPRESSION; TRANSFORMING GROWTH FACTOR BETA1;

3T3 CELLS; ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; FIBROBLASTS; GENE EXPRESSION; GENES, MYC; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; PHENOTYPE; TRANSFORMING GROWTH FACTOR BETA; VIRAL MATRIX PROTEINS;

EID: 0033058866     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050501     Document Type: Article

References (34)

1. Rickinson AB, Kieff E (1996) Fields Virology, vol 2, 3rd ed. Lippincott-Raven, New York, pp 2397-2446
2. Kieff E (1996) Fields Virology, vol 2, 3rd ed. Lippincott-Raven, New York, pp 2343-2396
3. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831-840
4. Baichwal VR, Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2: 461-467
5. Moorthy RK, Thorley LD (1993) All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 67: 1638-1646
6. Henderson S, Rowe M, Gregory C, Croom CD, Wang F, Longnecker, R, Kieff E, Rickinson A (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65: 1107-1115
7. Laherty C, Dixit VM (1992) The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 267: 24 157-24 160
8. Wang D, Liebowwitz D, Kieff E (1998) Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62: 4913-4184
9. Miller WE, Earp HS, Raab-Trab N (1995) The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69: 4 390-4 398
10. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80: 389-399
11. Martin J, Veis D, Korsmeyer S, Sugden B (1993) Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 67: 5 269-5 278
12. Rowe M, Peng PM, Huen DS, Hardy R, Croom CD, Lundgren E, Rickinson AB (1994) Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific repsonse that is delayed relative to NF-κB activation and to induction of cell surface markers. J Virol 68: 5 602-5 612
13. Arvanitakis L, Yaseen N, Sharma S (1995) Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J Immunol 155: 1 047-1 056
14. Liebowitz D, Mannick J, Takada K, Kieff E (1992) Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol 66: 4 612-4 616
15. Yuasa Y, Srivasta SK, Dunn CY, Rhim JS, Reddy EP, Aaronson SA (1983) Acquisition of transforming properties by alternative point mutations within c-bas/has human protooncogene. Nature 303: 775-779
16. Itoh T, Shiota M, Takanashi M, Hojo I, Satoh H, Matsuzawa A, Moriyama T, Watanabe T, Hirai K, Mori S (1993) Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer 72: 2 686-2 694
17. Sakaguchi M, Urakawa T, Hirayama Y, Miki N, Yamamoto M, Zhu G-S, Hirai K (1993) Marek's disease virus protein kinase gene identified within the short unique region of the viral genome is not essential for viral replication in cell culture and vaccine-induced immunity in chickens. Virology 195: 140-148
18. Lu JJ, Chen JY, Hsu TY, Yu WC, Su IJ, Yang CS (1996) Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J Gen Virol 77: 1 883-1 892
19. Lacy J, Summers WP, Summers WC (1989) Post-transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein-Barr virus. EMBO J 8: 1 973-1 980
20. Alfieri C, Birkenbach M, Kieff E (1991) Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181: 595-608
21. Amati B, Littlewood T, Evan G, Land H (1993) The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12: 5 083-5 087
22. Blackwood E, Eisenman R (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1 211-1 217
23. Ayer DE, Kretzner L, Eisenman RN (1993) Mad: a heteodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222
24. Zervos AS, Gyuris J, Brent R (1993) Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232
25. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J (1990) Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185
26. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Vogelstein B, Brattain M, Wilson JKV (1995) Inactivation of the type 11 TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1 336-1 338
27. Nicholson LJ, Hopwood P, Crawford DH (1997) Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene 15: 275-283
28. Sklar MD, Thompson E, Welsh MJ, Liebert M, Harney J, Grossman HB, Smith M, Prochownik EV (1991) Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol 11: 3 699-3 710
29. Missero C, Fivaroff E, Dotto GP (1991) Induction of transforming growth factor β1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. Proc Natl Acad Sci USA 88: 3 493-3 498
30. Satterwhite DJ, Moses HL (1994) Mechanisms of transforming growth factor-β1-induced cell cycle arrest. Invasion Meta 4: 309-318
31. Plyak K, Kato J-y, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994) p27kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22
32. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J (1993) Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260: 536-539
33. Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74
34. Ayer DE, Eisenman RN (1993) A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 7: 2 110-2 211